Related Experiment Video
Updated: Nov 7, 2025
Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing
Published on: October 15, 2019
Psoriasis and Gut Microbiome-Current State of Art
Karina Polak1, Beata Bergler-Czop2, Michał Szczepanek2
1Doctoral School, Medical University of Silesia, 40-055 Katowice, Poland.
Abstract:
Psoriasis is a chronic, immune-mediated inflammatory disease that affects around 125 million people worldwide. Several studies concerning the gut microbiota composition and its role in disease pathogenesis recently demonstrated significant alterations among psoriatic patients. Certain parameters such as Firmicutes/Bacteroidetes ratio or Psoriasis Microbiome Index were developed in order to distinguish between psoriatic and healthy individuals. The "leaky gut syndrome" and bacterial translocation is considered by some authors as a triggering factor for the onset of the disease, as it promotes chronic systemic inflammation. The alterations were also found to resemble those in inflammatory bowel diseases, obesity and certain cardiovascular diseases. Microbiota dysbiosis, depletion in SCFAs production, increased amount of produced TMAO, dysregulation of the pathways affecting the balance between lymphocytes populations seem to be the most significant findings concerning gut physiology in psoriatic patients. The gut microbiota may serve as a potential response-to-treatment biomarker in certain cases of biological treatment. Oral probiotics administration as well as fecal microbial transplantation were most reported in bringing health benefits to psoriatic patients. However, the issue of psoriatic bacterial gut composition, its role and healing potential needs further investigation. Here we reviewed the literature on the current state of the relationship between psoriasis and gut microbiome.
Insights
Psoriasis is linked to significant gut microbiome alterations, including changes in bacterial ratios and increased "leaky gut." These gut changes may influence disease development and response to treatments like probiotics.
Area of Science:
- Dermatology
- Microbiology
- Immunology
Background:
- Psoriasis is a chronic, immune-mediated inflammatory disease affecting 125 million globally.
- Gut microbiota alterations are increasingly recognized in psoriasis pathogenesis.
- Dysbiosis in psoriasis resembles changes seen in inflammatory bowel disease and obesity.
Purpose of the Study:
- To review the current literature on the relationship between psoriasis and the gut microbiome.
- To explore the role of gut microbiota composition in psoriasis development and progression.
- To discuss the potential of gut microbiota as a therapeutic target and biomarker.
Main Methods:
- Literature review of studies investigating psoriasis and gut microbiome.
- Analysis of key findings related to microbiota composition, dysbiosis, and associated physiological changes.
- Examination of potential therapeutic interventions targeting the gut microbiome.
Main Results:
- Psoriatic patients exhibit altered gut microbiota composition, including changes in Firmicutes/Bacteroidetes ratio and Psoriasis Microbiome Index.
- "Leaky gut syndrome" and bacterial translocation are implicated as potential triggers for systemic inflammation.
- Microbiota dysbiosis is associated with reduced short-chain fatty acid (SCFA) production and increased trimethylamine N-oxide (TMAO).
Conclusions:
- Gut microbiota dysbiosis is a significant factor in psoriasis, affecting immune responses and systemic inflammation.
- The gut microbiome shows potential as a biomarker for treatment response, particularly for biological therapies.
- Interventions like oral probiotics and fecal microbial transplantation may offer therapeutic benefits for psoriasis patients, warranting further investigation.
Related Concept Videos
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:17Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:11Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
01:05Physiology of Enteric Nervous System and Gut Health